Search Share Prices
Complexion brightens for SkinBioTherapeutics as company scores material transfer agreement
Life science company SkinBioTherapeutics has signed a material transfer agreement relating to its SkinBiotix technology with a major global consumer goods company, the firm announced on Tuesday.
The agreement with the unnamed company, which could lead to a commercial agreement, has been reached following the skin health specialists decision to share pre-clinical data with a number of interested parties.
The current material transfer agreement will see the consumer goods company assess the SkinBiotix technology before SkinBioTherapeutics moves forward with human studies later this year.
Cath O'Neill, chief executive of SkinBioTherapeutics, said: "Whilst these are early discussions, we are encouraged that a company of this calibre wants to look at our technology more closely through an MTA. Even at this early stage of its development, we are pleased to see that SkinBiotix is starting to generate a buzz in the skin care industry."
The company is initially targeting cosmetic skin care with SkinBiotix, which has demonstrated an ability to improve the skin barrier, enhance protection and protect from infection.
Potential opportunities for the technology include cosmetics, anti-infectives and treatment for conditions such as eczema.
As of 0937 BST, SkinBio Therapeutics' shares were up 5.88% at 9.00p.